Showing 1,095 results

Filters Content type: News, Editors' picks Topic: Hepatitis C treatment

Direct-acting antiviral medicines interfere with different steps of the hepatitis C lifecycle. A combination of drugs may be co-formulated into a single pill. Modern treatment typically lasts for two or three months, usually does not cause side-effects and cures more than 95% of treated people.

Hepatitis C treatment

SF working on ambitious plan to eliminate hepatitis C

Editor's pick
San Francisco Chronicle
21 February 2017
Hepatitis C treatment

Hepatitis C will be eradicated in Australia by 2026, researchers predict

Editor's pick
ABC Online
21 February 2017
Hepatitis C transmission & prevention

New hepatitis C infections among HIV-positive gay men drop by half after direct-acting antiviral roll-out in Netherlands

News
17 February 2017
Hepatitis C treatment

Curing hepatitis C reduces the risk of diabetes & kidney failure in people with HIV/HCV co-infection

News
1 February 2017
Hepatitis C treatment

HCV eradication in HIV coinfected patients linked to reduced diabetes, chronic renal failure

Editor's pick
Healio
31 January 2017
Hepatitis C treatment

Report Cites Liver Failure Risk With New Hepatitis C Drugs

Editor's pick
Medscape
31 January 2017
Hepatitis C symptoms & diagnosis

Liver cirrhosis and decompensation still on the rise among people with hepatitis C

News
31 January 2017
Hepatitis C treatment

Final yes from NICE for Gilead’s Epclusa

Editor's pick
Pharma Times
27 January 2017
Hepatitis C treatment

Is DAA treatment for hepatitis C reducing the need for liver transplants?

News
27 January 2017
Hepatitis C treatment

Egypt combats hepatitis C epidemic with state-run scheme

Editor's pick
Financial Times
23 January 2017
Hepatitis C treatment

Japan: Hepatitis C drug fakes found in Nara drugstore chain

Editor's pick
The Japan Times
18 January 2017
Pharmaceutical industry

The U.S. Government Should Buy Gilead For $156 Billion To Save Money On Hepatitis C

Editor's pick
Forbes
17 January 2017
Access to healthcare

Access to highly effective hepatitis C treatment in Portugal: A Community Perspective

Editor's pick
EATG
19 December 2016
Pharmaceutical industry

Gilead’s Patent Loss to Merck Started With a Broken Friendship

Editor's pick
Bloomberg
19 December 2016
Access to healthcare

Hepatitis C patients 'go abroad for drugs'

Editor's pick
BBC Radio 4 (audio)
19 December 2016
Pharmaceutical industry

Merck wins $2.54 billion in hepatitis C drug trial against Gilead

Editor's pick
Reuters
16 December 2016
People who inject drugs

Sofosbuvir-based therapy achieves excellent SVR12 rates among people who inject drugs in Ukraine

News
7 December 2016
Hepatitis C treatment

Hepatitis C drugs Australia's most expensive, cost taxpayers $1 billion in four months

Editor's pick
ABC Online
5 December 2016
Access to healthcare

New WHO report shows strategic purchasing of medicines can improve access in the European Region

Editor's pick
World Health Organization
2 December 2016
Hepatitis C treatment

DAA treatment restricted for Canadian hepatitis C patients

Editor's pick
Medical Economics
29 November 2016
Hepatitis C treatment

Sofosbuvir/ledipasvir is effective for people with HIV/HCV co-infection in real-world clinical practice

News
28 November 2016
Hepatitis C treatment

Grazoprevir triple regimen demonstrates high cure rates, even for hard-to-treat people

News
25 November 2016
Hepatitis C treatment

People with HIV/HCV co-infection see good cure rates in real-world practice in Madrid

News
23 November 2016
Hepatitis C treatment

8-week triple DAA combo cures most people with genotype 1-6 hepatitis C

News
21 November 2016